The Impact of <em>BRCA</em> Mutations in Ovarian Cancer
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the impact of BRCA mutations in ovarian cancer.
Clinical Pearls
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the impact of BRCA mutations in ovarian cancer.
- The cloning of theBRCAgenes in the early 1990s has allowed researchers to gain much insight about the biology of ovarian cancer
- BRCAgenes are involved in DNA repair
- The majority of ovarian cancers are high-grade serous, which start in the fallopian tubes, not the ovaries
- Researchers now have a better understanding of past challenges, how to guide therapeutics, and the need to focus on molecular subtypes
Recent Videos
Related Content
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024Article
In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
